ARK Investment Management LLC, more commonly known as ARK Invest, is an American investment management firm headquartered in ...

That's where CRISPR Therapeutics falls short. The company's approved product, Casgevy, is an ex vivo gene editing treatment.

Casgevy, the treatment procedure, is designed to work on the stem cells, so that the body produces a functioning haemoglobin.

From the first approved CRISPR treatment to AI designing its own computer chips, check out this week's awesome tech stories ...

With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...

It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...

Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...